Cambridge, United Kingdom – Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces that its genomic interpretation software is now CE marked under the In Vitro Diagnostics Directive (98/79/EC).
News
Increasing numbers of employees are being asked to self-isolate after being exposed to COVID, putting pressure on employers.
Employment lawyer, and Partner, Helen Farr was featured on BBC Radio 5 Live.
Click the link to listen.
SOMERSET, N.J. – July 21, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it will commence the first phase of a planned $100 million expansion program at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities, supporting the growing European market demand for biologics manufacture and supply.
20 July 2021: Future Fund: Breakthrough, announced by the Chancellor of the Exchequer at Budget 2021, opens today for applications. This UK-wide programme will deliver £375m of government funding via British Patient Capital, a commercial subsidiary of the British Business Bank.
NHS patients are set to benefit from early access to potentially life-saving new medicines, including cutting-edge gene therapies, thanks to a new Innovative Medicines Fund and £680 million of ringfenced funding, the NHS chief executive has announced today.
Cambridge, UK: 20 July 2021
One Nucleus, the non-for-profit Life Science membership group headquartered in Cambridge, exists to support growing Life Science businesses throughout their life cycle as they translate great science into better patient outcomes. This includes promoting and leveraging the world class excellence within our network and beyond, by facilitating the right connections.
We will not let hate suppress the success of others. We want to recognise the incredible achievements of the England #football team, and the hard work and strength they've inspired. They should be celebrated.
Everyone, whatever your profession, should have the support and freedom to excel.
We condemn the vicious and racist abuse of all professionals, whether that's online or otherwise, and stand in solidarity with other organisations and leaders who empower success unconditionally.
Today we announce our results for the financial year to 30 April 2021.
The firm has seen a 12% increase in UK revenue to £175.5m and a 23% increase in UK profit to £71m. UK profit per equity partner is 18% up on last year.
Cambridge, UK, 15 July 2021 – PharmEnable, an AI drug discovery company unlocking challenging biological targets, announces that it has entered into a drug discovery collaboration with LifeArc, an independent UK medical research charity, to apply their respective technologies and expertise to discover novel oral antiviral drugs with activity against coronaviruses.
AMSBIO has established an unmatched commercial biorepository and procurement network that includes a large selection of fully characterized and annotated Formalin-Fixed Paraffin-Embedded (FFPE) tissue blocks to help streamline your research.